Skip to main content

Hepatorenal Syndrome clinical trials at UCSF

1 research study open to eligible people

Hepatorenal Syndrome is when the kidneys do not work well due to liver disease. UCSF is recruiting for a clinical trial to test a treatment for people with Hepatorenal Syndrome-Acute Kidney Injury caused by cirrhosis with ascites. The trial is for testing the safety and effectiveness of the medicine OCE-205.

Showing trials for
  • A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

    open to eligible people ages 18-75

    OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites. The study aims are to evaluate the safety and efficacy of OCE-205 at various doses. Participants will receive treatment by intravenous infusion. Participants will continue with this treatment until participants meets primary endpoint or any discontinuation criteria.

    San Francisco, California and other locations

Last updated: